BLENREP
Clinical safety rating
cautionComprehensive clinical and safety monograph for BLENREP (BLENREP).
Comprehensive clinical and safety monograph for BLENREP (BLENREP).
FDA-approved for relapsed or refractory multiple myeloma in adults who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent
Belantamab mafodotin is an antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA) on multiple myeloma cells. The monoclonal antibody component binds to BCMA, leading to internalization and release of the cytotoxic agent monomethyl auristatin F (MMAF), which disrupts microtubule polymerization and induces apoptosis.
| Metabolism | Belantamab mafodotin is likely metabolized via proteolytic degradation into small peptides and amino acids; MMAF is a substrate of CYP3A and P-glycoprotein, but the contribution of CYP3A to clearance is limited. |
| Excretion | Blenrep (belantamab mafodotin) is eliminated primarily via catabolism, with no significant renal or biliary excretion of intact drug. The small molecule toxin, monomethyl auristatin F (MMAF), is excreted via feces (72%) and urine (28%) after release from the antibody conjugate. |
| Half-life | The terminal elimination half-life of belantamab mafodotin is approximately 12 days (range 9-19 days). This supports a dosing interval of every 3 weeks, allowing for drug clearance between cycles while maintaining therapeutic exposure. |
| Protein binding | Belantamab mafodotin is highly protein-bound (>99%) to plasma proteins, predominantly to albumin. The released MMAF is also extensively protein-bound (approximately 90% to albumin). |
| Volume of Distribution | The volume of distribution of belantamab mafodotin is approximately 7.8 L (range 4.5-12.4 L), which is slightly greater than plasma volume, indicating limited extravascular distribution. The Vd is not typically normalized to body weight; however, dosing is weight-based (mg/kg) to account for interpatient variability. |
| Bioavailability | Blenrep is administered as an intravenous infusion; thus, bioavailability is 100% by the intravenous route. No oral or other routes are approved. |
| Onset of Action | Onset of clinical response (e.g., partial response) is typically observed after 2 to 3 cycles (6-9 weeks) of intravenous administration at the recommended dose of 2.5 mg/kg every 3 weeks. |
| Duration of Action | Duration of response is variable, with median duration of response of approximately 8 months (range 1-20+ months) in clinical trials. Patients should be monitored for relapse and toxicity, particularly ocular effects, which may necessitate dose modifications. |
| Molecular Weight | 150000 |
2.5 mg/kg (actual body weight) intravenously over 30 minutes on day 1 of each 21-day cycle until disease progression or unacceptable toxicity.
| Dosage form | INJECTABLE |
| Renal impairment | For moderate renal impairment (eGFR 30-59 mL/min/1.73 m²): reduce dose to 1.9 mg/kg. For severe renal impairment (eGFR 15-29 mL/min/1.73 m²): not recommended. For eGFR <15 mL/min/1.73 m²: contraindicated. |
| Liver impairment | Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose to 1.9 mg/kg. Child-Pugh Class C: not recommended. |
| Pediatric use | Safety and efficacy not established; no specific pediatric dosing guidelines available. |
| Geriatric use | No specific dose adjustment recommended based on age alone; monitor renal function and consider dose adjustment per renal impairment guidelines. |
| 1st trimester | Avoid due to embryotoxicity based on mechanism of action (antibody-drug conjugate targeting BCMA) and animal studies showing fetal harm. |
| 2nd trimester | Avoid due to risk of fetal harm from the cytotoxic component (microtubule inhibitor). |
| 3rd trimester | Avoid due to potential neonatal adverse effects (e.g., myelosuppression, infection). |
Clinical note
Comprehensive clinical and safety monograph for BLENREP (BLENREP).
| Placental transfer | Belimumab is a human IgG1 monoclonal antibody; IgG is known to cross the placenta, especially in the third trimester. The antibody-drug conjugate may also cross the placenta based on molecular weight and structure. |
| Breastfeeding | Unknown if excreted in human milk; due to potential for serious adverse reactions (e.g., myelosuppression, neurotoxicity) in the breastfed infant, advise women not to breastfeed during treatment and for at least 2 weeks after the last dose. |
| Lactation Rating | L5 (Contraindicated) |
| Teratogenic Risk | FDA Pregnancy Category D. First trimester: belantamab mafodotin is an antibody-drug conjugate; the cytotoxic component may cause fetal harm. Second and third trimesters: risk of fetal toxicity and teratogenicity due to the microtubule inhibitor; avoid use unless maternal benefit outweighs risk. |
| Fetal Monitoring | Conduct pregnancy test before initiation. Monitor for ocular toxicity (keratopathy) with ophthalmic exams; renal function; hematologic toxicity (neutropenia, thrombocytopenia). No specific fetal monitoring recommended; serial ultrasounds if exposure occurs. |
| Fertility Effects | May impair male and female fertility. In animal studies, belantamab mafodotin caused testicular toxicity and reduced spermatogenesis; ovarian effects include follicular atresia. Advise patients to discuss fertility preservation before treatment. |
■ FDA Black Box Warning
WARNING: OCULAR TOXICITY. Blenrep (belantamab mafodotin) causes severe ocular toxicity, including keratopathy and changes in visual acuity, which may require dose modification or discontinuation. Perform ophthalmic exams prior to each dose. Use only in patients who have received at least 4 prior therapies.
| Serious Effects |
Known severe hypersensitivity to belantamab mafodotin or any excipients
| Precautions | Ocular toxicity (keratopathy, visual acuity changes), Thrombocytopenia, Infusion-related reactions, Hepatotoxicity (increased transaminases), Embryo-fetal toxicity |
| Food/Dietary | No specific food interactions known. Maintain adequate hydration. |
| Clinical Pearls | Monitor for ocular toxicity, including keratitis and uveitis; perform ophthalmic exams at baseline and during therapy. Premedicate with corticosteroids and vasoconstrictors to reduce infusion reactions. Blenrep is a BCMA-directed antibody-drug conjugate for relapsed/refractory multiple myeloma. Avoid in patients with severe renal impairment (CrCl <30 mL/min). |
| Patient Advice | Inform your doctor immediately if you experience blurred vision, eye pain, or light sensitivity. · You will need eye exams before and during treatment. · Report any signs of infusion reactions such as chills, fever, or difficulty breathing. · Use effective contraception during treatment and for 4 months after the last dose. · Avoid driving or operating machinery if you have vision changes. |
Loading safety data…